AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease
AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease |!| Mount Carm…
